Discovery Park selects 13 start-ups to join Discovery Spark life science programme

The 8-week programme offers in person training from industry leaders to build strong business foundations and prepare for investment. The Discovery Spark programme will equip the early-stage companies with the necessary skills to catalyse their business growth plans and gives them the chance to win a business support package worth over £100,000.

Finalists have the chance to win a business support package worth over £100,000, including one year of free lab space at Discovery Park and £50,000 investment from Discovery Park Ventures. The winner will be announced at the GIANT Health conference on 5th December 2023. 

The start-ups span across the biotech, digital tech, engineering biology, synthetic biology and medical technology sectors. Participants were chosen by a judging panel that scored the start-ups based on their product or service, opportunity and market, team management, programme fit and investment potential. Taking part in the programme will be 3D Synthesis, Awen, Bing Bong Biologics, BioMavericks, BugBiome, CardioCrown, DLOC Biosystems, Dravya Discovery, KASNMR, Matrix Bio, Rapidx Bio, The Future Care and XR-Musica.

As part of the programme, Discovery Park will host in-person training sessions, covering topics such as building an excellent team, understanding and conveying business metrics, and branding. The start-ups will also be able to take advantage of opportunities for networking, mentoring, learning from shared experiences and perfecting their investor pitch. The programme will culminate with an investor pitching event sponsored by Discovery Park as part of the GIANT Health conference on 5th December 2023. The start-up with the best pitch at the conference will win a business support package worth over £100,000. The package includes one free year of lab space at Discovery Park and £50,000 investment from Discovery Park Ventures, as well as comprehensive business support and mentoring.

Discovery Park’s Head of Innovation, Renos Savva, is leading the programme, bringing extensive experience in science entrepreneurship including co-founding Domainex and providing training for life science audiences across academia and industry. He said: “We were overwhelmed by the number of applications for Discovery Spark. The start-ups selected show phenomenal potential and we’re excited to accelerate their growth. Being investor-ready is essential for start-ups and Discovery Spark ensures participants will have the best team, brand image and business know-how by the end of the programme.”

BugBiome is harnessing the power of the skin microbiome to repel mosquitoes. Most mosquito repellents on the market provide protection for just a few hours and contain persistent synthetic chemicals that can harm the environment. BugBiome aims to utilise natural bacteria that repel mosquitoes to create an effective and safe solution. Alicia Showering, Founder and CEO at BugBiome, said: “We’re passionate about stopping the spread of deadly vector-borne diseases like malaria and Dengue by bringing longer-lasting natural repellents to market. Taking part in Discovery Spark will give us the necessary business tools to make this a reality.”

Delayed diagnosis of microbial diseases leads 15 million avoidable deaths every year. RapidX has developed a disease detection technology to deliver point of care diagnosis in under 30 minutes. Its technology doesn’t require specialist training to use and has important implications for the targeted treatment of diseases which will be vital to combat microbial drug resistance.

CardioCrown develops MedTech devices that empower stroke rehabilitation at home. Its integrated rehabilitation technology incorporates virtual reality, functional electrical stimulation and artificial intelligence to help accelerate the recovery of stroke patients. The engaging product will also reduce the time clinicians will have to spend with patients and help stroke units streamline processes.

Mayer Schreiber, CEO at Discovery Park, commented: “Not only will participants receive business training fine-tuned to life-science start-ups, but also access to Discovery Park’s cutting-edge facilities, where they will have the opportunity to network, ideate and collaborate. Discovery Park is committed to supporting the next generation of life science leaders, and our Discovery Spark programme embodies that.”
 

More news and updates 

Grey Wolf Therapeutics closes oversubscribed $50 million Series B financing expansion

Grey Wolf Therapeutics closes oversubscribed $50 million Series B Financing Expansion, led by ICG Life Sciences, to accelerate and expand first-of-its-kind antigen modulation technology. This brings the total Series B funds raised to nearly $100 million.

Somnus Scientific announces partnership with Life Science Group and Creonate

Somnus Scientific has agreed a collaborative partnership with Life Science Group (LSG) and Creonate Manufacturing for the next phase of product development.

Coulter Partners DEI: Views from leadership series - Ankit Mahadevia

In the latest instalment of its Diversity, Equity & Inclusion Leadership series, Coulter Partners spoke to Ankit Mahadevia, MD, Founder and Chair of Spero Therapeutics, and author of 'Quiet Leader, Loud Results'.

Discovery Park: Asymchem secures former Pfizer Sandwich, UK, development

Asymchem will operate the former Pfizer U.K. small molecule API pilot plant and part of the development laboratories through a new lease agreement between Asymchem and Discovery Park, establishing Asymchem’s first manufacturing footprint in Europe.

Ultra-concentrated, ultra-rapid acting insulin demonstrates superiority in Phase I clinical trial in Type 2 diabetics

AT278 demonstrates significantly accelerated PK/PD profile compared to NovoRapid® and Humulin® R U-500 in people with Type 2 Diabetes and high BMI

DLRC achieves King’s Award for Enterprise in International Trade

DLRC Ltd has been honoured with the King’s Award for Enterprise, recognising its outstanding performance in international trade. This places DLRC among a select group of only 252 organisations in the UK to receive this prestigious award.

Brainomix achieves breakthrough with FDA clearance of e-Lung AI software

Established market leader in stroke AI imaging receives its first FDA clearance in the lung imaging space; with this expanded foundation of AI-driven healthcare solutions, the Oxford-based company remains committed to driving innovation and delivering impactful advancements in imaging biomarkers.

Brainomix announces new studies further validating the impact of Brainomix 360 Stroke platform

With these latest studies, the firmly established European market leader in stroke AI imaging adds to its growing body of evidence; the latest research reflects the company’s extensive academic collaborations and its growing Life Science partnerships.

Optibrium partners with FMC Corporation to transform agrochemical discovery

Optibrium’s AI-powered discovery platform Cerella™ chosen by FMC to accelerate its agrochemical discovery pipeline.

New study shows Brainomix 360 AI transforms stroke treatment in England

The study represents the largest real-world evaluation of stroke artificial intelligence (AI) imaging, involving more than 80,000 patients at 26 sites over a 3-year period; the results showed Brainomix 360 Stroke was associated with an additional 50% increase in the number of patients receiving mechanical thrombectomy, while also improving the speed of treatment by 49 minutes.

 

More within